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 The likelihood of disability-free recovery after acute 
ischemic stroke is significantly improved by reperfusion 
either by intravenous thrombolytic drug treatment or with 
endovascular mechanical thrombectomy in selected cases. 
The use of intravenous thrombolysis is limited by the short 
treatment window and you need to assess individual balance 
of benefit and risk of symptomatic intracranial haemorrhage. 
Benefit is greater for shorter onset-to-reperfusion time 
intervals, requiring optimisation of pre-hospital and in-
hospital pathways. Symptomatic haemorrhage is more 
likely with more severe strokes, but a greater proportion of 
patients are left free of disability than suffer a treatment-
related haemorrhage at all levels of severity. Extracranial 
haemorrhage and orolingual angioedema are less common 
complications. Endovascular mechanical thrombectomy can 
be used in selected patients with imaging-proven large artery 
occlusion. Successful therapy depends on well-organised 
services that can deliver treatment within a short time 
window at centres with adequate expertise to perform the 
procedure. 
 Introduction 
 Brain tissue may be rescued if blood flow is restored rapidly 
after onset of acute ischemic stroke. Intravenous recombinant 
tissue plasminogen activator (IV rtPA) and, since 2015, 
endovascular thrombectomy (intra-arterial therapy, IAT) using 
stent retrievers can significantly improve the odds of disability-
free recovery. 
 Intravenous thrombolysis 
 Pooled individual patient data meta-analysis of 6,756 
patients in nine randomised controlled trials (RCTs) of 
IV rtPA show significantly increased likelihood of recovery 
to independence with treatment initiated up to 4.5 hours 
after symptom onset. The likelihood of favourable outcome 
declines rapidly with longer onset-to-treatment times: the 
number needed to treat (NNT) for excellent functional 
outcome is five for treatment within 90 minutes, nine for 
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treatment within 91–180 minutes, and 19 for treatment 
within 181–270 minutes after onset. 1 
 Clinical uptake of IV rtPA remains limited by a clinically 
challenging diagnosis, short therapeutic time window and the 
need to balance risk and benefit in individuals, taking into 
account relative contraindications. 2 Service organisation to 
optimise pre- and in-hospital pathways can, however, result 
in 20% of patients being eligible using current guidelines. 3 
While there are some clear contraindications, many ‘legacy’ 
contraindications arising from older clinical trials and 
reflected in the drug label have been superseded in light of 
evidence of equivalent safety and efficacy. 4 There is net benefit 
for IV rtPA across all strata of severity and age with respect 
to reduction in disability, the dominant outcome after stroke 
(suggested framework in Fig  1 ). 
Key points
 Intravenous recombinant tissue plasminogen activator (IV rtPA) 
given within 4.5 hours of symptom onset significantly increases 
the likelihood of recovery to independence 
 Greater benefit is seen with shorter onset-to-treatment times 
and services should minimise delay in instituting treatment 
 Symptomatic intracranial bleeding is the most severe possible 
complication of IV rtPA; other complications include systemic 
bleeding and orolingual oedema 
 The treatment decision depends on balancing the possibility 
of good clinical outcome against the risk of intracranial 
bleeding 
 Endovascular mechanical thrombectomy improves the chances 
of good outcome in a subset of patients with large vessel 
occlusion 
 Complications of endovascular procedures include those related 
to vascular access, radiological contrast media and device-
related vascular injury 
 KEYWORDS: Cerebrovascular disease, endovascular treatment, 
stroke, thrombectomy, thrombolysis ■ 
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 Indications and contraindications 
 Treatment decisions should take into account individual risk–
benefit balance and may be informed by modelled RCT data 
illustrating outcomes in different strata of severity and onset-to-
treatment time. 5 While the relative benefit of treatment remains 
constant across age groups and severities, the absolute benefit 
varies by time to treatment and should be balanced against 
the risk of symptomatic intracerebral haemorrhage (SICH). 
Relative risk of SICH appears constant across the first 4.5 hours. 
Since risk of SICH increases with stroke severity, and with the 
presence of pre-existing brain imaging abnormalities such as old 
ischaemia, absolute excess SICH risk increases with increasing 
stroke severity. However, risk factors for SICH are also those 
that predict poor outcome from stroke without treatment 
(eg advanced age, high blood glucose, more severe stroke, 
pre-existing computerised tomography (CT) changes) and 
treatment net benefit is consistent across all of these subgroups. 
 Effects in very mild stroke (National Institutes of Health Stroke 
Scale (NIHSS) score ≤5) are imprecisely characterised, prompting 
further clinical trials in this situation. 6 Clinical judgement should 
be preferred to neurological scores: very significant deficits may 
be associated with low NIHSS scores (for example, complete 
hemianopia or isolated dysphasia), while very high NIHSS scores 
(>25) are predominantly seen in posterior circulation stroke. 7 
 Brain imaging is essential to exclude intracranial haemorrhage 
and established recent ischaemia. Other structural intracranial 
pathologies were excluded from clinical trials largely to ensure 
Paent with sudden onset of focal neurological deficit
No thrombolysis
NOIndicaons for IV rtPA:
• clinical picture consistent with acute stroke
• last seen well less than 4.5 hours ago
YES
No thrombolysis
YES
Absolute contraindicaons for IV rtPA:
• arterial blood pressure more than 185 systolic or 110 diastolic despite
   treatment
• high risk of bleeding
 • INR>1.6
 • PT>15
 • platelet count<100,000
 • hereditary or acquired bleeding disorders
 • use of therapeuc doses of IV or oral ancoagulants within the
    last 48 hours
• extensive hypodensity on inial brain CT
• evidence of intracranial haemorrhage on inial brain CT
• recent extensive trauma (including surgery, arterial or lumbar puncture)
• high risk of intracranial pathology, eg glioblastoma
Possible
thrombolysis
YES
NO
Thrombolysis
risk benefit
Relave contraindicaons for IV rtPA:
• NIHSS>25
• blood sugar<2 mmol/L or >18 mmol/L with persistence of symptoms
   on treatment
• recent minor trauma or surgery
• low risk intracranial structural lesions, eg meningioma, small
   asymptomac aneurysm
• seizure at onset
• previous intracranial haemorrhage
• pregnancy or postpartum
• recent myocardial infarcon
NO
 Fig 1.  Indications and contraindications 
of thrombolysis. CT = computerised to-
mography; INR = international normalised 
ratio; IV rtPA = intravenous recombinant 
tissue plasminogen activator; NIHSS = 
National Institutes of Health Stroke Scale; 
PT = prothrombin time 
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correct diagnosis and, therefore, there are very limited data on 
safety or efficacy in patients with other structural lesions. The 
presence of anatomically extensive hypodensity is a marker 
of extensive irreversible ischaemia (a ‘large ischaemic core’) 
and signifies a worse prognosis although the relative treatment 
effect of IV rtPA does not differ in this group. 8,9 Multimodal 
imaging, including CT or magnetic resonance angiography and 
MRI or CT perfusion (CTP) imaging, yields information on 
intracranial vessels and brain perfusion, and can differentiate 
between ischaemic core and potentially reversible ischaemia 
(the penumbra). 10 While imaging features, especially large 
ischaemic core volumes and poor collateral vessel status, are 
strongly linked to prognosis, 11 an interaction with treatment 
effect is not established. 12 
 Treatment is contraindicated in conditions where there 
is considered to be a high risk of intracranial or systematic 
haemorrhage. 13 These include coagulopathies and elevated 
blood pressure (>185 mmHg systolic or >110 mmHg diastolic by 
licence). Data from registries, case-control studies and large case 
series show thrombolysis to be of similar safety and effectiveness 
in a range of clinical situations previously considered relative 
contraindications, including history of previous stroke and 
diabetes, stroke due to dissection, recent stroke (>6 weeks ago), 
minor silent subacute stroke, hypertension within the range 
<185/110 mmHg, increased international normalised ratio <1.7, 
myocardial infarction more than 7 weeks earlier, asymptomatic 
intracranial aneurysms, presence of early ischaemic change 
on CT, leukoaraiosis, MRI-defined cerebral microbleeds and 
very severe stroke. The third International Stroke Trial (IST-3) 
included patients with a broader range of baseline characteristics 
than earlier trials undertaken to establish efficacy and found 
no significant modification of treatment effect by a range 
of characteristics, including early ischaemic change on CT, 
presence of leukoaraiosis, baseline blood pressure (including 
some patients with elevated blood pressure beyond licence 
guidelines), blood glucose, age, stroke severity, prior antiplatelet 
therapy use, history of diabetes or atrial fibrillation. 9 
 Complications 
 Minor systemic bleeding is common at sites of trauma (eg 
venepuncture sites, gums, oropharynx and minor injuries). 
SICH is the complication most likely to have functional 
importance. The widely used European Cooperative Acute 
Stroke Study radiological classification of ICH (Fig  2 ) is 
combined with clinical change in various ways across study 
reports and rates of SICH range from 2–6% depending on 
the definition. Only parenchymal haematoma type 2 bleeds 
have been associated independently with poor outcome, while 
haemorrhagic infarction is associated with reperfusion. 11,14 
Several factors increase SICH risk, 15,16 but stroke severity 
is the strongest predictor (with or without thrombolysis). 17  
Excess risk of SICH rises from 1.5% for NIHSS 0–4 to 3.7% 
for NIHSS>25 (Fig  2 ). There is no evidence to support pro-
coagulant therapy or surgical intervention for SICH. 
 Rates of extra-cranial haemorrhage after IV rtPA varied from 
2–7%, but no consistent definition has been used and treatment 
has been dictated by site and volume of bleeding. 18 
 Orolingual angioedema, an idiosyncratic acute swelling of the 
lips and tongue, is associated with prior angiotensin converting 
enzyme inhibitor therapy and occurs in 1–8% of patients 
receiving IV rtPA. Cases may be unilateral or bilateral, and 
occur 15 minutes to a few hours after therapy. Approximately 
70% of cases are classed as mild, with 12% sufficiently severe 
to compromise breathing. Most cases resolve spontaneously 
or with the use of corticosteroids or antihistamines. 19 Other 
allergic reactions to IV rtPA are rarely reported. 20 
 Neurological deterioration after IV rtPA is more than 
twice as likely to be caused by non-haemorrhagic factors 
(recurrent ischaemic stroke, brain swelling or non-attributable 
deterioration) than SICH. 21 Systemic illness, including 
infection, hypoxia or other reversible causes, may all worsen a 
patient's neurological condition and should be sought. 
 Mechanical endovascular thrombectomy 
 Early recanalisation after IV rtPA is infrequent in occlusions 
of large intracranial vessels (<10% of terminal internal carotid 
artery or 25% of middle cerebral artery M1 segment) 22 and 
where there is a large clot burden. Occlusions of these sites 
are therefore associated with very severe stroke and poor 
outcome, but likelihood of early recanalisation is lowest with 
IV rtPA. Endovascular mechanical thrombectomy was shown 
to be effective in this group of patients in five RCTs published 
in 2015 (and confirmed in three others), with significantly 
improved odds of favourable outcome compared with best 
medical care alone (including IV thrombolysis in 90% of 
randomised patients). It has an NNT of 8 to achieve excellent 
clinical outcome and an NNT of 3 to move to a more favourable 
functional outcome. There was no increase in mortality or 
SICH incidence. 23 All positive trials used stent-retriever devices, 
which may achieve recanalisation in up to 87% of patients. 
 All trials selected patients with large artery occlusion using CT 
angiography. In three trials, additional selection to enrich the 
population using perfusion or vascular collateral imaging was 
undertaken. Centres provided highly organised, high-volume 
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 Fig 2.  Risk of symptomatic intracerebral haemorrhage (SICH) and 
absolute increase in proportion of patients with excellent functional 
outcome at 3–6 months after stroke by stroke severity (National 
Institutes of Health Stroke Scale (NIHSS)). These represent the 
difference in absolute outcomes between intravenous recombinant tissue 
plasminogen activator (IV rtPA)-treated patients and control groups 
adjusted for age and treatment delay. Modelled excess SICH risks for NIHSS 
strata were adjusted for age and treatment delay. Data derived from 
Whiteley  et al. 5 
CMJv17n2-CME_Muir.indd   163 25/02/17   4:11 PM
CME Cerebrovascular disease
164 © Royal College of Physicians 2017. All rights reserved.
in clinical trials reflect practice at expert neurovascular centres, 
undertaken by interventional neuro-radiologists in almost all 
cases; whether the same complication rates will pertain to other 
operators or service configurations is not known. 
 Incorporating mechanical thrombectomy in routine stroke 
care is logistically challenging. The number of patients eligible 
for therapy is likely to be 10–15% of rtPA treated patients. 
Centres and individual operators that perform IAT need to treat 
sufficient cases to maintain efficacy and quality of service. 29 
Clinical and imaging criteria that should prompt patient transfer 
to a neuro-interventional stroke centre will vary with population 
density and regional distribution of facilities and expertise. 30 
 Conclusions 
 Reperfusion by intravenous thrombolysis or endovascular 
mechanical thrombectomy improves functional outcomes 
after stroke, but benefit for both treatment modalities is highly 
time-dependent. Maximum benefit requires minimisation 
of onset-to-treatment times. The safety and efficacy of IV 
rtPA is established across a broad range of clinical scenarios. 
Endovascular treatment now offers greatly improved outcome 
among patients with poor response to IV rtPA but efficacy 
has been established only in the context of highly organised 
neurovascular interventional services. ■ 
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 Complications of endovascular procedures include those 
related to vascular access, radiological contrast media and 
device-related vascular injury. Use of general anaesthesia 
was associated with less favourable outcome compared with 
sedation in a non-randomised, post-hoc comparison and further 
trials are in progress to address this question. 25 Puncture site 
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in any of the recent IAT trials. The complication rates quoted 
Haemorrhagic infarct
H1: small petechial
along the margins of
the infarct
H2: confluent petechiae
within the infarcted area
but no space occupying
effect
Parenchymal haemorrhage
PH1: blood clots in ≤30%
of the infarcted area with
space occupying effect
PH2: blood clots in >30%
of the infarcted area with
space occupying effect Fig 3.  Classifi cation of post- 
thrombolysis haemorrhage. 
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